Abbvie-Header Abbvie-Header

X

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Shanghai SIMR Biotechnology

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CHINA China

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Arab Health 2021

              Participation Not Confirmed

              Update your events

              Shanghai SIMR Biotechnology's First Patient Successfully Dosed with the Candidate Drug SR419 for Peripheral Neuropathic Pain

              Contact the Supplier

              Lead Product(s): SR419

              Therapeutic Area: Neurology Product Name: SR419

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 20, 2020

              Details:

              The current clinical trial is the first study for SR419 in the patient population, purposing to explore the efficacy, safety, tolerability and pharmacokinetics of SR419 in patients with neuropathic pain.

              PharmaCompass__DigitalAd